\n\u00a0<\/p>\n<\/td>\n
9M 2026<\/b><\/p>\n<\/td>\n
% Change<\/b><\/p>\n<\/td>\n
Q3 2026<\/b><\/p>\n<\/td>\n
% Change<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n $m<\/b><\/p>\n<\/td>\n Actual<\/b><\/p>\n<\/td>\n CER1<\/sup><\/b><\/p>\n<\/td>\n $m<\/b><\/p>\n<\/td>\n Actual<\/b><\/p>\n<\/td>\n CER<\/b><\/p>\n<\/td>\n<\/tr>\n – Product Sales<\/i><\/p>\n<\/td>\n 43,962<\/i><\/p>\n<\/td>\n 7<\/i><\/p>\n<\/td>\n 5<\/i><\/p>\n<\/td>\n 15,066<\/i><\/p>\n<\/td>\n 5<\/i><\/p>\n<\/td>\n 5<\/i><\/p>\n<\/td>\n<\/tr>\n – Alliance Revenue<\/i><\/p>\n<\/td>\n 2,806<\/i><\/p>\n<\/td>\n 33<\/i><\/p>\n<\/td>\n 32<\/i><\/p>\n<\/td>\n 1,107<\/i><\/p>\n<\/td>\n 36<\/i><\/p>\n<\/td>\n 36<\/i><\/p>\n<\/td>\n<\/tr>\n \nProduct Revenue<\/p>\n<\/td>\n \n46,768<\/p>\n<\/td>\n \n8<\/p>\n<\/td>\n \n6<\/p>\n<\/td>\n \n16,173<\/p>\n<\/td>\n \n7<\/p>\n<\/td>\n \n7<\/p>\n<\/td>\n<\/tr>\n \nCollaboration Revenue<\/p>\n<\/td>\n \n113<\/p>\n<\/td>\n \n22<\/p>\n<\/td>\n \n23<\/p>\n<\/td>\n \n36<\/p>\n<\/td>\n \n>3x<\/p>\n<\/td>\n \n>3x<\/p>\n<\/td>\n<\/tr>\n Total Revenue<\/b><\/p>\n<\/td>\n 46,881<\/b><\/p>\n<\/td>\n 8<\/b><\/p>\n<\/td>\n 7<\/b><\/p>\n<\/td>\n 16,209<\/b><\/p>\n<\/td>\n 7<\/b><\/p>\n<\/td>\n 7<\/b><\/p>\n<\/td>\n<\/tr>\n Reported EPS ($)<\/b><\/p>\n<\/td>\n 5.62<\/b><\/p>\n<\/td>\n 10<\/b><\/p>\n<\/td>\n 11<\/b><\/p>\n<\/td>\n 2.02<\/b><\/p>\n<\/td>\n 23<\/b><\/p>\n<\/td>\n 26<\/b><\/p>\n<\/td>\n<\/tr>\n Core<\/b>2<\/sup>EPS($)<\/b><\/p>\n<\/td>\n 8.00<\/b><\/p>\n<\/td>\n 14<\/b><\/p>\n<\/td>\n 14<\/b><\/p>\n<\/td>\n 2.79<\/b><\/p>\n<\/td>\n 17<\/b><\/p>\n<\/td>\n 19<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n Key performance elements for 9M 2026<\/span><\/p>\n \n(Growth numbers at constant exchange rates)<\/p>\n Pascal Soriot, Chief Executive Officer, AstraZeneca, said:<\/span><\/p>\n \n\u201cIn the first nine months we saw strong commercial momentum with total revenue up 7% and Core EPS up 14%, driven by our diverse therapy areas and global presence. We have had approvals for four new medicines and reported 12 positive Phase III programme readouts with a collective peak year revenue potential well in excess of ten billion dollars. Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars.<\/p>\n \nWith multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition and to sustain growth through the next decade.\u201d<\/p>\n Guidance<\/span><\/p>\n \nAstraZeneca reconfirms Total Revenue and Core EPS guidance3<\/sup> for FY 2026 at CER, based on the average foreign exchange rates through 2025.<\/p>\n Total Revenue<\/b> is expected to increase by a mid-to<\/b>–high single-digit<\/b> percentage<\/p>\n Core EPS<\/b> is expected to increase by a low double-digit<\/b> percentage<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nThe Core Tax rate is expected to be between 18-22%<\/p>\n \nIf foreign exchange rates for October 2026 to December 2026 were to remain at the average rates seen in September 2026, it is anticipated that Total Revenue in FY 2026 would benefit from a low single-digit percentage positive impact (unchanged) compared to the performance at CER, and Core EPS growth would be broadly similar (unchanged) to the growth at CER.<\/p>\n \nResults highlights<\/p>\n \nTable 1: Milestones achieved since the prior results announcement<\/p>\n \nPhase III and other registrational data readouts<\/p>\n Medicine<\/b><\/p>\n<\/td>\n Trial<\/b><\/p>\n<\/td>\n Indication<\/b><\/p>\n<\/td>\n Event<\/b><\/p>\n<\/td>\n<\/tr>\n Enhertu<\/i><\/p>\n<\/td>\n \nDESTINY-Lung04<\/p>\n<\/td>\n \n1L HER2<\/i>m NSCLC<\/p>\n<\/td>\n \nPrimary endpoint met<\/p>\n<\/td>\n<\/tr>\n Etcamah<\/i><\/p>\n<\/td>\n \nSERENA-4<\/p>\n<\/td>\n \n1L HR+ HER2- advanced breast cancer<\/p>\n<\/td>\n \nPrimary endpoint not met<\/p>\n<\/td>\n<\/tr>\n Imfinzi<\/i> + tarlatamab<\/p>\n<\/td>\n \nDeLLphi-305<\/p>\n<\/td>\n \n1L ES-SCLC (maintenance)<\/p>\n<\/td>\n \nPrimary endpoint met<\/p>\n<\/td>\n<\/tr>\n Lynparza<\/i><\/p>\n<\/td>\n \nMONO-OLA1<\/p>\n<\/td>\n \n1L BRCAwt ovarian cancer<\/p>\n<\/td>\n \nDual primary endpoints met<\/p>\n<\/td>\n<\/tr>\n Tagrisso<\/i> + Orpathys<\/i><\/p>\n<\/td>\n \nSAFFRON<\/p>\n<\/td>\n \n2L+ EGFR<\/i>m, MET-overexpressed and\/or amplified NSCLC<\/p>\n<\/td>\n \nPrimary endpoint met<\/p>\n<\/td>\n<\/tr>\n Tagrisso<\/i> + Orpathys<\/i><\/p>\n<\/td>\n \nSANOVO<\/p>\n<\/td>\n \n1L EGFR<\/i>m, MET-overexpressed NSCLC<\/p>\n<\/td>\n \nPrimary endpoint met<\/p>\n<\/td>\n<\/tr>\n \nvolrustomig<\/p>\n<\/td>\n \neVOLVE-Lung02<\/p>\n<\/td>\n \n1L PD-L1 <50% mNSCLC<\/p>\n<\/td>\n \nDiscontinued due to futility<\/p>\n<\/td>\n<\/tr>\n Tezspire<\/i><\/p>\n<\/td>\n \nCROSSING<\/p>\n<\/td>\n \nEosinophilic esophagitis<\/p>\n<\/td>\n \nCo-primary endpoints met<\/p>\n<\/td>\n<\/tr>\n Ultomiris<\/i><\/p>\n<\/td>\n \nAWAKE<\/p>\n<\/td>\n \nDelayed Graft Function<\/p>\n<\/td>\n \nDiscontinued due to lack of efficacy<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nRegulatory approvals<\/p>\n Medicine<\/b><\/p>\n<\/td>\n Trial<\/b><\/p>\n<\/td>\n Indication<\/b><\/p>\n<\/td>\n Region<\/b><\/p>\n<\/td>\n<\/tr>\n Datroway<\/i><\/p>\n<\/td>\n \nTROPION-Breast02<\/p>\n<\/td>\n \n1L TNBC for patients where immunotherapy is not an option<\/p>\n<\/td>\n \nEU, JP, CN<\/p>\n<\/td>\n<\/tr>\n Enhertu<\/i><\/p>\n<\/td>\n \nDESTINY-Breast09<\/p>\n<\/td>\n \n1L HER2+ mBC<\/p>\n<\/td>\n \nEU, JP, CN<\/p>\n<\/td>\n<\/tr>\n Enhertu<\/i><\/p>\n<\/td>\n \nDESTINY-Breast05<\/p>\n<\/td>\n \nHigh-risk HER2+ early breast cancer (post-neoadjuvant)<\/p>\n<\/td>\n \nEU, CN<\/p>\n<\/td>\n<\/tr>\n Enhertu<\/i><\/p>\n<\/td>\n \nDESTINY-PanTumor02<\/p>\n<\/td>\n \nHER2+ solid tumours<\/p>\n<\/td>\n \nCN<\/p>\n<\/td>\n<\/tr>\n Etcamah<\/i><\/p>\n<\/td>\n \nSERENA-6<\/p>\n<\/td>\n ESR1<\/i>m HR+ HER2- 1L advanced breast cancer<\/p>\n<\/td>\n \nUS<\/p>\n<\/td>\n<\/tr>\n Imfinzi<\/i><\/p>\n<\/td>\n \nPOTOMAC<\/p>\n<\/td>\n \nNMIBC<\/p>\n<\/td>\n \nJP<\/p>\n<\/td>\n<\/tr>\n Breztri<\/i><\/p>\n<\/td>\n \nKALOS \/ LOGOS<\/p>\n<\/td>\n \nAsthma<\/p>\n<\/td>\n \nEU, JP<\/p>\n<\/td>\n<\/tr>\n Klygefa<\/i> (gefurulimab)<\/p>\n<\/td>\n \nPREVAIL<\/p>\n<\/td>\n \nGeneralised myasthenia gravis<\/p>\n<\/td>\n \nJP<\/p>\n<\/td>\n<\/tr>\n Amlypave<\/i> (anselamimab)<\/p>\n<\/td>\n \nCARES<\/p>\n<\/td>\n \nKappa light chain amyloidosis<\/p>\n<\/td>\n \nJP<\/p>\n<\/td>\n<\/tr>\n Ultomiris<\/i><\/p>\n<\/td>\n \nI CAN<\/p>\n<\/td>\n \nIgAN<\/p>\n<\/td>\n \nUS<\/p>\n<\/td>\n<\/tr>\n Ultomiris<\/i><\/p>\n<\/td>\n \nALXN1210-PNH-323<\/p>\n<\/td>\n \nPNH<\/p>\n<\/td>\n \nCN<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nRegulatory submissions or acceptances* in major regions<\/p>\n Medicine<\/b><\/p>\n<\/td>\n Trial<\/b><\/p>\n<\/td>\n Indication<\/b><\/p>\n<\/td>\n Region<\/b><\/p>\n<\/td>\n<\/tr>\n Calquence<\/i><\/p>\n<\/td>\n \nAMPLIFY<\/p>\n<\/td>\n \n1L CLL (fixed duration)<\/p>\n<\/td>\n \nCN<\/p>\n<\/td>\n<\/tr>\n Imfinzi<\/i><\/p>\n<\/td>\n \nVOLGA<\/p>\n<\/td>\n \nMIBC not candidates for cisplatin<\/p>\n<\/td>\n \nUS, EU, JP<\/p>\n<\/td>\n<\/tr>\n Truqap<\/i><\/p>\n<\/td>\n \nCAPItello-281<\/p>\n<\/td>\n \nPTEN-deficient mHSPC<\/p>\n<\/td>\n \nCN<\/p>\n<\/td>\n<\/tr>\n \ntozorakimab<\/p>\n<\/td>\n \nOBERON \/ TITANIA \/ PROSPERO<\/p>\n<\/td>\n \nCOPD<\/p>\n<\/td>\n \nUS, JP<\/p>\n<\/td>\n<\/tr>\n Ultomiris<\/i><\/p>\n<\/td>\n \nI CAN<\/p>\n<\/td>\n \nIgAN<\/p>\n<\/td>\n \nCN<\/p>\n<\/td>\n<\/tr>\n Ultomiris<\/i><\/p>\n<\/td>\n \nALXN1210-TMA-314<\/p>\n<\/td>\n \nHSCT-TMA (paediatric)<\/p>\n<\/td>\n \nUS<\/p>\n<\/td>\n<\/tr>\n \nefzimfotase alfa<\/p>\n<\/td>\n \nMULBERRY \/ CHESTNUT \/ HICKORY<\/p>\n<\/td>\n \nHPP<\/p>\n<\/td>\n \nUS, EU, CN<\/p>\n<\/td>\n<\/tr>\n * US, EU and China regulatory entries in this table denote filing acceptance<\/i><\/p>\n<\/td>\n<\/tr>\n<\/table>\n Other pipeline updates<\/span><\/p>\n \nFor recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix document in the financial results section of the AstraZeneca investor relations website: www.astrazeneca.com\/investor-relations.html<\/a><\/p>\n \nTable 2: Key elements of financial performance: Q3 2026<\/p>\n \nFor the quarter<\/b><\/p>\n<\/td>\n Reported<\/b><\/p>\n<\/td>\n Change<\/b><\/p>\n<\/td>\n Core<\/b><\/p>\n<\/td>\n Change<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nended 30 September<\/p>\n<\/td>\n $m<\/b><\/p>\n<\/td>\n Act<\/b><\/p>\n<\/td>\n CER<\/b><\/p>\n<\/td>\n $m<\/b><\/p>\n<\/td>\n Act<\/b><\/p>\n<\/td>\n CER<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nProduct Revenue<\/p>\n<\/td>\n \n16,173<\/p>\n<\/td>\n \n7<\/p>\n<\/td>\n \n7<\/p>\n<\/td>\n \n16,173<\/p>\n<\/td>\n \n7<\/p>\n<\/td>\n \n7<\/p>\n<\/td>\n \n* See Tables 3, 7, 23, 24 and 25 for further details of Product Revenue, Product Sales and Alliance Revenue<\/p>\n<\/td>\n<\/tr>\n \nCollaboration Revenue<\/p>\n<\/td>\n \n36<\/p>\n<\/td>\n \n>3x<\/p>\n<\/td>\n \n>3x<\/p>\n<\/td>\n \n36<\/p>\n<\/td>\n \n>3x<\/p>\n<\/td>\n \n>3x<\/p>\n<\/td>\n \n* See Tables 4 and 26 for further details of Collaboration Revenue<\/p>\n<\/td>\n<\/tr>\n \nTotal Revenue<\/p>\n<\/td>\n \n16,209<\/p>\n<\/td>\n \n7<\/p>\n<\/td>\n \n7<\/p>\n<\/td>\n \n16,209<\/p>\n<\/td>\n \n7<\/p>\n<\/td>\n \n7<\/p>\n<\/td>\n \n* See Tables 5 and 6 for Total Revenue by Therapy Area and by region<\/p>\n<\/td>\n<\/tr>\n \nGross Margin (%)<\/p>\n<\/td>\n \n82<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n+1pp<\/p>\n<\/td>\n \n82<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n+1pp<\/p>\n<\/td>\n \n+ Positive product mix effects<\/p>\n \n\u2212 Pricing headwinds, including those driven by loss of exclusivity and VBP in China<\/p>\n \n* Variations in Gross Margin can be expected between periods due to various factors, including fluctuations in foreign exchange rates, product seasonality and Collaboration Revenue<\/p>\n<\/td>\n<\/tr>\n \nR&D expense<\/p>\n<\/td>\n \n3,894<\/p>\n<\/td>\n \n6<\/p>\n<\/td>\n \n7<\/p>\n<\/td>\n \n3,645<\/p>\n<\/td>\n \n3<\/p>\n<\/td>\n \n3<\/p>\n<\/td>\n \n* Core R&D: 22% of Total Revenue (23% for 9M 2026)<\/p>\n \n+ Increasing number of trials, and patients in those trials<\/p>\n \n+ Investments in transformative technologies<\/p>\n \n+ Addition of R&D projects from business development<\/p>\n \n+ Positive data readouts for high value pipeline opportunities that have ungated large late-stage trials<\/p>\n \n* Variations in the year-on-year change in R&D expenses can be expected between periods due to the phasing of trial starts and completions<\/p>\n<\/td>\n<\/tr>\n \nSG&A expense<\/p>\n<\/td>\n \n5,108<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n3,909<\/p>\n<\/td>\n \n2<\/p>\n<\/td>\n \n2<\/p>\n<\/td>\n \n* Core SG&A: 24% of Total Revenue (25% for 9M 2026)<\/p>\n \n+ Investment to support ongoing and future launches<\/p>\n \n* Variations in the year-on-year change in SG&A expenses can be expected between periods due to the phasing of product launches and other programmes<\/p>\n<\/td>\n<\/tr>\n \nOther operating income and expense4<\/sup><\/p>\n<\/td>\n \n277<\/p>\n<\/td>\n \n>3x<\/p>\n<\/td>\n \n>3x<\/p>\n<\/td>\n \n277<\/p>\n<\/td>\n \n>2x<\/p>\n<\/td>\n \n>2x<\/p>\n<\/td>\n \n+ Various partner milestones and royalties<\/p>\n \n+ Disposal of Zoryve interest<\/p>\n<\/td>\n<\/tr>\n \nOperating profit<\/p>\n<\/td>\n \n4,387<\/p>\n<\/td>\n \n22<\/p>\n<\/td>\n \n26<\/p>\n<\/td>\n \n5,855<\/p>\n<\/td>\n \n17<\/p>\n<\/td>\n \n20<\/p>\n<\/td>\n \n+ See commentary above on Gross Margin, R&D, SG&A and Other operating income and expense<\/p>\n<\/td>\n<\/tr>\n \nOperating Margin (%)<\/p>\n<\/td>\n \n27<\/p>\n<\/td>\n \n+3pp<\/p>\n<\/td>\n \n+4pp<\/p>\n<\/td>\n \n36<\/p>\n<\/td>\n \n+3pp<\/p>\n<\/td>\n \n+4pp<\/p>\n<\/td>\n<\/tr>\n \nNet finance expense<\/p>\n<\/td>\n \n410<\/p>\n<\/td>\n \n17<\/p>\n<\/td>\n \n22<\/p>\n<\/td>\n \n371<\/p>\n<\/td>\n \n22<\/p>\n<\/td>\n \n27<\/p>\n<\/td>\n \n+ Lower interest income on short-term deposits and higher interest expense on short-term borrowings<\/p>\n \n+ Higher discount unwind on lease liabilities, principally due to the new strategic R&D centre in Massachusetts, US<\/p>\n \n\u2212 Reported Net finance expense benefitted from a lower discount unwind on contingent consideration liabilities<\/p>\n<\/td>\n<\/tr>\n \nTax rate (%)<\/p>\n<\/td>\n \n21<\/p>\n<\/td>\n \n-1pp<\/p>\n<\/td>\n \n-1pp<\/p>\n<\/td>\n \n21<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n-1pp<\/p>\n<\/td>\n \n* Variations in the tax rate can be expected between periods<\/p>\n<\/td>\n<\/tr>\n \nEPS ($)<\/p>\n<\/td>\n \n2.02<\/p>\n<\/td>\n \n23<\/p>\n<\/td>\n \n26<\/p>\n<\/td>\n \n2.79<\/p>\n<\/td>\n \n17<\/p>\n<\/td>\n \n19<\/p>\n<\/td>\n \n+ See commentary above<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n For dollar values in this table, the unit of change is percent. For Gross Margin, Operating Margin and Tax rate, the unit of change is percentage points (pp).<\/i><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n In the table above, R&D expense, SG&A expense and Net finance expense are displayed as positive numbers. The plus and minus symbols next to comments denote the directional impact of the item being discussed. For example, a plus symbol next to a comment about an R&D item indicates that the item increased R&D expenditure relative to the prior year period.<\/i><\/p>\n<\/td>\n<\/tr>\n<\/table>\n Corporate and business development<\/span><\/p>\n Summit Therapeutics \nAstraZeneca and Summit entered into a clinical collaboration agreement to evaluate sonesitatug vedotin in combination with Summit\u2019s PD-1\/VEGF bispecific antibody ivonescimab. The two companies also entered into a clinical collaboration with Daiichi Sankyo to evaluate Datroway<\/i> in combination with ivonescimab.<\/p>\n \nAstraZeneca and Summit intend to enter into an additional agreement initiating a global development programme combining other AstraZeneca cancer medicines, including additional ADCs, with ivonescimab.<\/p>\n Kendall Square R&D Centre Reshaping for Sustainable Growth insitro \nUnder the terms of the agreement, insitro will receive an upfront payment of $40m, and is also eligible for up to approximately $1.46bn in potential development and commercial milestones, plus potential single digit royalties based on global commercial sales. AstraZeneca will have exclusive worldwide rights to advance selected programmes identified under the collaboration.<\/p>\n Dizal Pharmaceutical Co Sustainability highlights<\/span><\/p>\n \nAstraZeneca ranked fifth on TIME Magazine\u2019s 2026 World\u2019s Best Companies list – its highest position to date and the top ranking among pharmaceutical companies – based on sustainability transparency, revenue growth, and employee satisfaction.<\/p>\n Reporting calendar<\/span><\/p>\n \nThe Company intends to publish its FY and Q4 2026 results on 9 February 2027.<\/p>\n Conference call<\/span><\/p>\n \nA conference call and webcast for investors and analysts will begin today, 30 October 2026, at 14:30 UK time. Details can be accessed via astrazeneca.com<\/a>.<\/p>\n Notes<\/span><\/p>\n \nTo read AstraZeneca’s 9M & Q3 2026 Financial Results press release in full, read here<\/a>.<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20261029477587\/en\/<\/a><\/span><\/p>\n \nGlobal Media Relations team KEYWORDS:<\/b> United Kingdom Europe<\/p>\n INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical Oncology General Health Health Clinical Trials<\/p>\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n
\n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n<\/b>
In October AstraZeneca completed a $2bn equity investment in Summit Therapeutics Inc. (Summit). The investment gives AstraZeneca rights equivalent to approximately 12.0% of Summit Therapeutics\u2019 outstanding common stock, or approximately 10.6% on a fully diluted basis.<\/p>\n
\n<\/b>
In October, AstraZeneca formally opened its new global strategic R&D centre, in Kendall Square, Cambridge, Massachusetts. The state-of-the-art facility builds on the Company\u2019s existing presence in Boston and Cambridge, Massachusetts and will be home to nearly 2,000 world-class researchers and scientists.<\/p>\n
\n<\/b>
AstraZeneca is in a catalyst rich period with more than 180 pipeline projects driving its next wave of growth and scientific innovation. To capitalise on this opportunity, the Company has initiated the Reshaping for Sustainable Growth (RSG) programme to create additional capacity to invest behind its industry-leading pipeline and transformative technologies. Over the next three years, the programme will redeploy resources and strengthen capabilities across AstraZeneca\u2019s existing business and therapy areas. The RSG programme is expected to cost up to $2.0bn in one-time restructuring costs and deliver $1.5bn in annualised pre-tax run-rate benefits. The savings generated will continue to be reinvested back into the Company, principally in the pipeline. The Company anticipates activities to be essentially complete by the end of 2029.<\/p>\n
\n<\/b>
In October, AstraZeneca entered into a strategic drug discovery collaboration and licensing agreement with insitro. Using advanced AI systems, the collaboration will identify novel drug targets and advance the design of new therapeutics for MASH and cardiomyopathies.<\/p>\n
\n<\/b>
In August, AstraZeneca completed the license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy<\/i>, which is approved in the US and China for the 2nd-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. See Interim Financial Statements, Note 5, for further details.<\/p>\n\n
<\/p>\n
\n
global-mediateam@astrazeneca.com
\n<\/a>
+44 (0)1223 344 800<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20261029477587\/en\/2301168\/3\/original.jpg\")
<\/td>\n<\/tr>\n